UPDATE: Exact Sciences' Q1 Revenues Drop 23 Percent
May 03, 2011
UPDATE: Exact Sciences' Q1 Revenues Drop 23 Percent
As the firm moves toward clinical trials for its Cologuard colorectal cancer test, almost all of Exact Sciences' revenues were from licensing deals, while product revenues dropped to $4,000 from $12,000 a year ago.
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.
Related Stories
- Data from Exact Sciences' Clinical Trial Sends Stock Plunging
April 18, 2013 / GenomeWeb Daily News - Exact Sciences Posts Flat Q2 Revenues
July 25, 2012 / GenomeWeb Daily News - Biodesix Receives US Patents Covering VeriStrat Test
April 15, 2011 / ProteoMonitor - CDC Group Finds No Evidence to Support Use of LabCorp's ColoSure Test in General Risk Population
March 23, 2011 / Pharmacogenomics Reporter - Exact Sciences Files Second Module of PMA Application with FDA
February 18, 2013 / GenomeWeb Daily News